Nature, Published online: 18 September 2026; doi:10.1038/d41586-026-02946-y Affected Chinese companies adjusted their sources of knowledge to stay competitive.
Nature
Original source
Nature, Published online: 18 September 2026; doi:10.1038/d41586-026-02946-y Affected Chinese companies adjusted their sources of knowledge to stay competitive.
Nature
Original source

Dualitas Therapeutics has announced a research collaboration and licence agreement with Roche to discover and develop novel bispecific antibody (BsAb) therapies for immunology and inflammation (I&I) diseases. The DualScreenTM platform is designed to support high-throughput discovery of bispecific antibodies based on proximity biology. Unlike conventional approaches that typically begin with selected target pairs, the platform evaluates a broad range of targets and epitopes

SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity announces new Hong Kong patent that protects the proprietary technology behind its noninvasive CyPath Lung diagnostic for lung cancer.

DURHAM, N.C.--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced the continuation of its long-standing partnership with Prevention Access Campaign (PAC) – the founding organization behind the Undetectable = Untransmittable (U=U) movement. To celebrate 10 years of U=U, ViiV Healthcare is joining PAC to introduce “Undetectable Voices,” a new digital storytelling and community engagement campaign that builds on

IIT Bhubaneswar, IIT (ISM) Dhanbad join hands for semiconductor research
Headlines and briefs on this site are for information only. Always verify details on the original source or live status page.
Read Disclaimer